In this webcast, panelists will discuss life sciences transfer pricing controversy trends and developments in the US.
The latest EY report How to navigate global transfer pricing controversy in life sciences explores the growing tax authority scrutiny that life sciences companies are facing with regard to their transfer pricing practices. The unique attributes of the life sciences industry, coupled with an increasingly unpredictable legal and tax regulatory environment, and significant fiscal pressures faced by governments worldwide, have focused tax authorities’ attention on the industry and placed life sciences companies in the cross hairs.
Please join us in this webcast during which we will explore life sciences transfer pricing controversy trends and developments in the US. Our team of life sciences and transfer pricing specialists will discuss and share their perspectives on emerging trends and hot topics relevant to this market, including:
- Global transfer pricing controversy issues and trends developing across the sector
- Evolving controversy trends, audit approaches and things to look out for in the US market
- Practical actions and key takeaways for life sciences multinationals to prepare for increasing and intensifying transfer pricing controversy
Panelists:
- Ana Maria Romero, EY US-East Operating Model Effectiveness Transfer Pricing Leader
- Dan Sosna, Managing Director, International Tax and Transaction Services, Transfer Pricing, Ernst & Young LLP
- Helena Aten, Senior Manager, International Tax and Transaction Services, Transfer Pricing, Ernst & Young LLP
- Marla McClure, Managing Director, International Tax & Transaction Services, Transfer Pricing, Ernst & Young LLP
- Mike McDonald, Managing Director, International Tax and Transaction Services, Transfer Pricing, Ernst & Young LLP
To go to Asia-Pacific and Europe-focused session, click here.
